Search
Filter by content type
Filter by content year
BioNTech veröffentlicht endgültige Ergebnisse des Umtauschangebots für CureVac
December 18, 2025 - … darunter Bristol Myers Squibb, Duality Biologics, Fosun Pharma, Genentech (ein Unternehmen der Roche Gruppe), … darunter Bristol Myers Squibb, Duality Biologics, Fosun Pharma, Genentech (ein Unternehmen der Roche Gruppe), … darunter Bristol Myers Squibb, Duality Biologics, Fosun Pharma, Genentech (ein Unternehmen der Roche Gruppe), …
BioNTech Publishes Final Results of the Exchange Offer for CureVac
December 18, 2025 - … including Bristol Myers Squibb, Duality Biologics, Fosun Pharma, Genentech, a member of the Roche Group, Genmab, … including Bristol Myers Squibb, Duality Biologics, Fosun Pharma, Genentech, a member of the Roche Group, Genmab, … including Bristol Myers Squibb, Duality Biologics, Fosun Pharma, Genentech, a member of the Roche Group, Genmab, …
BioNTech schließt Übernahme von CureVac N.V. samt damit verbundener Nachangebotsfrist ab und stärkt so die einzigartige Position im mRNA-Feld
December 18, 2025 - … darunter Bristol Myers Squibb, Duality Biologics, Fosun Pharma, Genentech (ein Unternehmen der Roche Gruppe), … darunter Bristol Myers Squibb, Duality Biologics, Fosun Pharma, Genentech (ein Unternehmen der Roche Gruppe), … darunter Bristol Myers Squibb, Duality Biologics, Fosun Pharma, Genentech (ein Unternehmen der Roche Gruppe), …
BioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA Field
December 18, 2025 - … including Bristol Myers Squibb, Duality Biologics, Fosun Pharma, Genentech, a member of the Roche Group, Genmab, … including Bristol Myers Squibb, Duality Biologics, Fosun Pharma, Genentech, a member of the Roche Group, Genmab, … including Bristol Myers Squibb, Duality Biologics, Fosun Pharma, Genentech, a member of the Roche Group, Genmab, …
Erste Ergebnisse aus BioNTechs und BMS’ globaler Phase-2-Studie mit bispezifischem PD-L1xVEGF-A-Antikörperkandidat Pumitamig zeigten ermutigende Anti-Tumor-Aktivität bei fortgeschrittenem dreifach negativem Brustkrebs
December 9, 2025 - … darunter Bristol Myers Squibb, Duality Biologics, Fosun Pharma, Genentech (ein Unternehmen der Roche Gruppe), … darunter Bristol Myers Squibb, Duality Biologics, Fosun Pharma, Genentech (ein Unternehmen der Roche Gruppe), … darunter Bristol Myers Squibb, Duality Biologics, Fosun Pharma, Genentech (ein Unternehmen der Roche Gruppe), …
BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer
December 9, 2025 - … including Bristol Myers Squibb, Duality Biologics, Fosun Pharma, Genentech, a member of the Roche Group, Genmab, … including Bristol Myers Squibb, Duality Biologics, Fosun Pharma, Genentech, a member of the Roche Group, Genmab, … including Bristol Myers Squibb, Duality Biologics, Fosun Pharma, Genentech, a member of the Roche Group, Genmab, …
BioNTechs und OncoC4s selektiver Treg-Modulatorkandidat Gotistobart erzielte klinisch relevanten Gesamtüberlebensvorteil bei Patientinnen und Patienten mit zuvor behandeltem Plattenepithelkarzinom der Lunge
December 6, 2025 - … darunter Bristol Myers Squibb, Duality Biologics, Fosun Pharma, Genentech (ein Unternehmen der Roche Gruppe), … darunter Bristol Myers Squibb, Duality Biologics, Fosun Pharma, Genentech (ein Unternehmen der Roche Gruppe), … darunter Bristol Myers Squibb, Duality Biologics, Fosun Pharma, Genentech (ein Unternehmen der Roche Gruppe), …
BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer
December 6, 2025 - … including Bristol Myers Squibb, Duality Biologics, Fosun Pharma, Genentech, a member of the Roche Group, Genmab, … including Bristol Myers Squibb, Duality Biologics, Fosun Pharma, Genentech, a member of the Roche Group, Genmab, … including Bristol Myers Squibb, Duality Biologics, Fosun Pharma, Genentech, a member of the Roche Group, Genmab, …
BioNTech erfüllt Mindestannahmebedingungen im Rahmen des Umtauschangebots für CureVac-Aktien
December 3, 2025 - … darunter Bristol Myers Squibb, Duality Biologics, Fosun Pharma, Genentech (ein Unternehmen der Roche Gruppe), … darunter Bristol Myers Squibb, Duality Biologics, Fosun Pharma, Genentech (ein Unternehmen der Roche Gruppe), … darunter Bristol Myers Squibb, Duality Biologics, Fosun Pharma, Genentech (ein Unternehmen der Roche Gruppe), …
BioNTech Achieves Minimum Condition in CureVac Exchange Offer
December 3, 2025 - … including Bristol Myers Squibb, Duality Biologics, Fosun Pharma, Genentech, a member of the Roche Group, … including Bristol Myers Squibb, Duality Biologics, Fosun Pharma, Genentech, a member of the Roche Group, … including Bristol Myers Squibb, Duality Biologics, Fosun Pharma, Genentech, a member of the Roche Group, …
